Despite a historically lower median survival of patients with IDH wild-type tumors compared to IDH-mutant tumors (1.2 vs. 3.6 years) [26,27], supramarginal resection in patients < 65 years with IDH wild-type GBM led to a median overall survival comparable to IDH mutant tumors. The gene discussed is IDH1; the disease is glioblastoma.